See more : Build King Holdings Limited (0240.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Adlai Nortye Ltd. American Depositary Shares (ANL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adlai Nortye Ltd. American Depositary Shares, a leading company in the Biotechnology industry within the Healthcare sector.
- Taisei Corporation (1801.T) Income Statement Analysis – Financial Results
- Snowsky Salt Industry Group Co., Ltd. (600929.SS) Income Statement Analysis – Financial Results
- Anupam Rasayan India Limited (ANURAS.NS) Income Statement Analysis – Financial Results
- Charoen Pokphand Foods Public Company Limited (CPOF.F) Income Statement Analysis – Financial Results
- Arisawa Mfg. Co., Ltd. (5208.T) Income Statement Analysis – Financial Results
Adlai Nortye Ltd. American Depositary Shares (ANL)
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.00M | 0.00 | 45.73M | 0.00 | 0.00 |
| Cost of Revenue | 2.22M | 2.04M | 0.00 | 1.51M | 1.48M |
| Gross Profit | 2.78M | -2.04M | 45.73M | -1.51M | -1.48M |
| Gross Profit Ratio | 55.56% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 58.15M | 54.49M | 42.11M | 19.04M | 13.34M |
| General & Administrative | 15.29M | 13.04M | 12.45M | 6.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | -968.12K | 0.00 |
| SG&A | 15.29M | 13.04M | 12.45M | 5.56M | 4.30M |
| Other Expenses | 0.00 | 7.88M | -46.77M | 0.00 | 0.00 |
| Operating Expenses | 72.55M | 67.27M | 54.37M | 24.59M | 17.64M |
| Cost & Expenses | 73.38M | 67.27M | 54.37M | 26.10M | 19.12M |
| Interest Income | 61.95K | 550.00K | 32.00K | 24.05K | 22.87K |
| Interest Expense | 791.00K | 433.00K | 579.00K | 1.75M | 466.15K |
| Depreciation & Amortization | 2.22M | 2.04M | 1.83M | 1.51M | 1.48M |
| EBITDA | -101.22M | -65.41M | -7.01M | -24.59M | -17.64M |
| EBITDA Ratio | -2,026.06% | 0.00% | -118.84% | 0.00% | 0.00% |
| Operating Income | -67.55M | -67.27M | -8.65M | -26.10M | -19.12M |
| Operating Income Ratio | -1,352.20% | 0.00% | -18.91% | 0.00% | 0.00% |
| Total Other Income/Expenses | -36.68M | 8.48M | -48.03M | -37.28M | 1.29M |
| Income Before Tax | -104.23M | -58.79M | -56.68M | -63.38M | -17.83M |
| Income Before Tax Ratio | -2,086.37% | 0.00% | -123.95% | 0.00% | 0.00% |
| Income Tax Expense | 643.00K | 8.31M | -46.19M | 3.00 | -1.00 |
| Net Income | -104.87M | -58.79M | -56.68M | -63.38M | -17.83M |
| Net Income Ratio | -2,099.25% | 0.00% | -123.95% | 0.00% | 0.00% |
| EPS | -7.26 | -6.93 | -6.68 | -7.64 | -2.10 |
| EPS Diluted | -7.26 | -6.93 | -6.68 | -7.64 | -2.10 |
| Weighted Avg Shares Out | 14.45M | 8.48M | 8.48M | 8.48M | 8.48M |
| Weighted Avg Shares Out (Dil) | 14.45M | 8.48M | 8.48M | 8.48M | 8.48M |
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap
U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices
IPO Update: Adlai Nortye Readies $72 Million U.S. IPO
Cancer treatment company Adlai Nortye sets terms in IPO
Source: https://incomestatements.info
Category: Stock Reports